Innovent Biologics First Half 2025 Earnings: EPS: CN¥0.51 (vs CN¥0.24 loss in 1H 2024)

Simply Wall St · 08/28 23:33

Innovent Biologics (HKG:1801) First Half 2025 Results

Key Financial Results

  • Revenue: CN¥5.95b (up 51% from 1H 2024).
  • Net income: CN¥834.3m (up from CN¥392.6m loss in 1H 2024).
  • Profit margin: 14% (up from net loss in 1H 2024).
  • EPS: CN¥0.51 (up from CN¥0.24 loss in 1H 2024).
earnings-and-revenue-growth
SEHK:1801 Earnings and Revenue Growth August 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innovent Biologics Earnings Insights

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 8.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Innovent Biologics you should know about.